71785-46-1

Usage

Type of compound

Heterocyclic compound

Structural components

Contains a pyrazole and quinazolinone ring system

Pharmaceutical applications

Interacts with biological receptors and enzymes

Usage

Building block in organic synthesis and drug discovery processes

Potential

Development of new drugs with therapeutic potential for various diseases and conditions

Research and development

Interesting subject in the field of medicinal chemistry due to unique molecular structure and potential pharmacological activities

Upstream product

• 75844-29-0 1-acetyl-5-methyl-6-nitro-1H-indazole 
• 75844-32-5 1-Acetyl-6-(acetylamino)-1H-indazol-5-carbonsaeure 
• 75844-31-4 6-Nitro-1H-indazol-5-carbonsaeure-methylester 
• 75844-38-1 6-Nitro-1H-indazol-5-carbonsaeure 
• 75844-30-3 1-Acetyl-6-(acetylamino)-5-methyl-1H-indazol 
• 72521-00-7 5-methyl-6-nitro-1H-indazole 
• 75844-28-9 5-methyl-6-amino-1H-indazole 
• 75844-33-6 6-amino-indazol-5-carboxylic acid 
• 77287-34-4 formamide 

Downstream Products

• 73908-01-7 pyrazolo<4,3-g>quinazoline-5,7-dione 
• 81237-60-7 1H-pyrazolo[4,3-g]quinazoline-5(6H)-thione 
• 174709-35-4 (3-Bromo-phenyl)-(1H-pyrazolo[4,3-g]quinazolin-5-yl)-amine 

Relevant academic research and scientific papers

Quinazoline derivatives

Novel quinazoline derivatives of the formula (1) STR1 wherein ring C is a pyrazole ring fused to ring B in two vicinal positions thereof that are not fused with ring A. The novel formula (1) compounds or pyrazolo-quinazoline-ones are structurally related to allopurinol, a well known drug useful in the treatment of gout and are expected to replace or complement allopurinol in the therapeutic use thereof. The generic name Benzoallopurinol is suggested for the novel formula (1) compounds; formula (1) includes angular and linear structures of the interfused rings A, B and C. Two methods for producing the novel formula (1) compounds are disclosed. The first method starts from the indazole structure that includes the interfused rings B and C, and ring A is formed on the indazole moiety. The second method starts from the quinazoline structure that includes interfused rings A and B, and the pyrazole ring C is formed on the benzo moiety (ring B) of the quinazoline structure. Either method may lead to angular or linear benzoallopurinols depending upon the substituents introduced into the starting structure for forming the complemental ring thereon.